Bluebird bio has now secured FDA approvals for two lentiviral vector gene therapies for rare diseases. Melissa Bonner, the company’s head of research, discusses the rocky road to success and ...

The lentiviral vector market is rapidly growing, driven by advancements in gene therapy and increasing demand for innovative medical treatments. In 2023, the market was valued at USD 176.8 million and ...

Gene therapy with lentiviral vector–transduced HSCs, as compared with AAV gene therapy, for hemophilia A overcomes nearly all the limitations related to highly variable and unpredictable ...

He went on to found Lentigen, a company that developed the lentiviral vector used in Kymriah, which originated at Penn and under Novartis became the first FDA-approved CAR T-cell therapy.

UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...

Veteran CDMO executive to guide next phase of global expansion and operational excellence for lentiviral vector manufacturer.

Lentiviral Vector Market report encompasses a range of inhibitors as well as driving forces of the market which are analysed in both qualitative and quantitative manner so that readers and users get ...

“The applications of lentiviral vectors are diverse,” she says, pointing out that while 65% of the CDMO’s customers are developing immunotherapies, like CAR-Ts, TCRs, NK-CARs, NK-TCRs, TILs ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform.. The deal will see AstraZeneca scoop up all ...